CD19 and acute lymphoblastic leukemia: Since 2017, seven FDA approvals on CAR products for hematological cancers have been registered3,4, including anti-CD19 CAR T cells for relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), showing complete remission (CR) in 70–96% of patients5–14.